Timothy grass pollen allergen proteins (Phl p allergens)

Timothy grass (Phleum pratense) pollen proteins are potent environmental allergens responsible for seasonal allergic rhinitis, conjunctivitis, and asthma (Source: NIH, MedlinePlus). These proteins, including major allergens such as Phl p 1 and Phl p 5, contain specific epitopes that trigger IgE-mediated hypersensitivity reactions in sensitized individuals (Source: WHO/IUIS Allergen Nomenclature Sub-Committee). Upon exposure, these epitopes cross-link IgE antibodies on the surface of mast cells and basophils, leading to the release of inflammatory mediators like histamine (Source: StatPearls, Type I Hypersensitivity). In clinical practice, these allergen proteins are the primary targets of allergen immunotherapy (AIT), which involves the controlled administration of the allergen to modify the patient's immune response (Source: Journal of Allergy and Clinical Immunology). AIT works by inducing peripheral T-cell tolerance, promoting the development of regulatory T cells (Tregs), and stimulating the production of allergen-specific IgG4 antibodies that block IgE binding (Source: Nature Reviews Immunology). This therapeutic approach aims to provide long-term relief and prevent the progression of allergic disease by shifting the immune system from a Th2 to a Th1/Treg profile. Understanding the molecular structure of these epitopes is crucial for developing standardized extracts and recombinant vaccines for more precise treatment (Source: UniProt). These proteins are often administered sublingually or subcutaneously in standardized dosages, such as in the drugs Grazax or Oralair, to ensure safety and efficacy (Source: FDA, Grazax Prescribing Information).

Other names

Phleum pratense allergensTimothy grass allergensPhl p 1Phl p 5Grass pollen allergensTimothy grass pollen allergen epitopes

Allergen immunotherapy (AIT) induces immune tolerance by shifting the immune response from a Th2-dominated profile to a Th1/Treg-dominated profile, increasing the production of blocking antibodies (IgG4 and IgA) and reducing IgE-mediated mast cell degranulation.